Komori
Daiken Medical (7775) · InitiativeRestated

Strengthening R&D for Innovative Products

First written in FY2017-Q1. 24 of 27 entries say "Restated". Latest entry: 2026-07-31.

27entries
11years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017-Q3 – FY2026-H12016: 220162017: 420172018: 420182019: 220192020: 220202021: 220212022: 220222023: 320232024: 220242025: 220252026: 22026
Same theme, other companies
Originality as the Source of New Value and Market CreationA theme 8 companies write about · 0 as a headwind · 8 as a tailwind

4 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  2. FY2026-H1RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    The company continues to strengthen research and development activities for original products.
  3. FY2025RestatedAnnual report

    「独創的な製品に結びつくような企画、研究、開発を推し進めております。」

    独創的で高付加価値な製品の研究開発を強化する方針を継続している。
  4. FY2025-H1RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    独創的な製品の研究開発活動を強化する方針を継続している。
  5. FY2024-Q3RestatedAnnual report

    「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」

    The company continues to strengthen research and development activities for original products.
  6. FY2024-Q2RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    独創的な製品の研究開発活動を強化する方針を継続している。
  7. FY2024-Q1RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    独創的な製品の研究開発活動を強化する方針を継続している。
  8. FY2023-Q3RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    独創的な製品の研究開発活動を強化する方針を継続している。
  9. FY2023-Q2RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    独創的な製品の研究開発活動を強化する方針を継続している。
  10. FY2022RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    独創的な製品の研究開発活動を強化する方針を継続している。
  11. FY2022-Q1RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    独創的な製品の研究開発活動を強化する方針を継続している。
  12. FY2021RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    The company continues to strengthen research and development activities for original products.
  13. FY2020RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    The company continues to strengthen research and development activities for original products.
  14. FY2020-Q3RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    The company continues to strengthen research and development activities for original products.
  15. FY2019RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    The company continues to strengthen research and development activities for original products.
  16. FY2019-Q3RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    The company continues to strengthen research and development activities for original products.
  17. FY2019-Q2RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    The company continues to strengthen research and development activities for original products.
  18. FY2019-Q1RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    The company continues to strengthen research and development activities for original products.
  19. FY2018RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    The company continues to strengthen research and development activities for original products.
  20. FY2018-Q3RestatedAnnual report

    「Against this backdrop, the Company made the consistent, stable supply of high-quality products a priority and worked to strengthen sales activities closely aligned with users, establish a cost-competitive production system while maintaining quality, and reinforce research and development of original products.」

    The company continues to strengthen research and development activities for original products.
  21. FY2018-Q2RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    独創的な製品の研究開発活動の強化を引き続き掲げている。
  22. FY2018-Q1RestatedAnnual report

    「Strengthening R&D activities for innovative products」

    独創的な製品の研究開発活動の強化を引き続き掲げている。
  23. FY2017RestatedAnnual report

    「独創的な製品の研究開発活動をより一層強化し」

    独創的な製品の研究開発活動を一層強化する方針を継続している。
  24. FY2017-Q3RestatedAnnual report

    「高度先進医療分野への研究開発活動の強化」

    高度先進医療分野への研究開発活動の強化を引き続き掲げている。
  25. FY2017-Q2ReframedAnnual report

    「高度先進医療分野への研究開発活動の強化」

    研究開発強化という施策は継続しているが、今回の記載では「独創的な製品」ではなく「高度先進医療分野」への注力が明示されている。
  26. FY2017-Q1First statedAnnual report

    「Strengthening R&D activities for innovative products」

    Strengthening R&D activities focused on creating innovative products.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Daiken Medical's next results are scheduled for 2026-10-30. Read the earnings preview It last moved in the Earnings of 2026-07-31: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.